SavedAdd your journal

Journals / Retina-Vitreus / 2010 / Cilt: 18 - Sayı: 2

Results of intravitreal ranibizumab treatment for choroidal neovascularization secondary to age-related macular degeneration

Yaşa bağlı maküla dejenerasyonuna ikincil gelişen koroid neovaskülarizasyonlarında intravitreal ranibizumab tedavi sonuçlarımız

ELVAN ALPER ŞENGÜL
Özgür ARTUNAY
Özgür YÜZBAŞIOĞLU
RIFAT RASİER
Amber ŞENEL
Halil BAHÇECİOĞLU
Pages
143–148
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusions: IVR provides significant anatomic and functional improvement compared the baseline in choroidal neovascularization due to ARMD.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Purpose: To report the efficacy and results of intravitreal ranibizumab (IVR) injection for choroidal neovascularization due to age-related macular degeneration (ARMD).
📊
Key Findings & Data:Materials and Methods: Fifty-eight eyes of 43 ARMD patients received 287 injections of 0.5 mg/0.05 mL IVR and were followed up for at least one year prospectively.
💡
Conclusion & Impact:Conclusions: IVR provides significant anatomic and functional improvement compared the baseline in choroidal neovascularization due to ARMD.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Purpose: To report the efficacy and results of intravitreal ranibizumab (IVR) injection for choroidal neovascularization due to age-related macular degeneration (ARMD). Materials and Methods: Fifty-eight eyes of 43 ARMD patients received 287 injections of 0.5 mg/0.05 mL IVR and were followed up for at least one year prospectively. The mean age was 67.64 ± 8.14. All patients received three consecutive monthly IVR injections. IVR injections were readministered based on visual acuity (VA) measurements, fundus fluorescein angiography (FFA), and optic coherence tomography (OCT) results. Results: By three months, 28 eyes (48.3%) had an increase in VA of 5 letters or more, 27 eyes (46.5%) had no change, and 3 eyes (5.2%) had a decrease of 5 letters or more. After the 12-month follow-up VA results were as follows: 26 eyes (44.8%) had an increase of 5 letters or more, 28 eyes (48.3%) had no change, and 4 eyes (6.9%) had a decrease of 5 letters or more. In 44 eyes (75.9%), central macular thickness (CMT) decreased by 100 μm or more, in 12 eyes (20.7%) there was no change, and in 2 eyes (3.4%) CMT increased by 100 μm or more at the third month. After the 12-month follow-up, CMT decreased by 100 μm or more in 42 eyes (72.4%) and increased by 100 μm or more in 3 eyes (5.2%), while 13 eyes (22.4%) had no change. Conclusions: IVR provides significant anatomic and functional improvement compared the baseline in choroidal neovascularization due to ARMD.

Özet

Amaç: Yaşa bağlı maküla dejenerasyonuna (YBMD) bağlı gelişen koroid neovaskülarizasyonunda intravitreal ranibizumabın (İVR) etkinliğini araştırmak ve sonuçlarımızı bildirmek. Gereç ve Yöntem: Kırk üç YBMD hastasının, 58 gözüne 287 İVR (0.5 mg/0.05 mL) enjeksiyonu uygulanmıştır ve hastalar prospektif olarak en az bir yıl süreyle takip edilmiştir. Hastaların ortalama yaşı 67.64±8.14 idi. Her hastaya birer ay arayla 3 enjeksiyon yapıldıktan sonra hastaların görme keskinliği (GK), fundus floresein anjiyografi (FFA) ve optik koherens tomografi (OKT) sonuçları değerlendirilerek enjeksiyon tekrarına karar verilmiştir. Bulgular: ETDRS eşeli ile ölçülen görme keskinliklerine göre 3. ayda 5 harf ve üzeri artış gösteren 28 göz (%48.3), değişim göstermeyen 27 göz (%46.5) ve 5 harf ve üzeri düşüş gösteren 3 göz (%5.2) olduğu tespit edilirken 12. ay sonunda sırasıyla 26 göz (%44.8), 28 göz (%48.3) ve 4 göz (%6.9) bulundu. OKT ile belirlenen maküla kalınlıklarına göre 3. ayda 100 μm ve üzeri azalma gösteren 44 göz (%75.9), değişme gözlenmeyen 12 göz (%20.7) ve maküla kalınlığında artış olan 2 göz (%3.4) olduğu bulunurken 12. ayda sırasıyla 42 göz (%72.4), 13 göz (%22.4) ve 3 göz (%5.2) tespit edildi. Sonuç: Yaşa bağlı maküla dejenerasyonuna bağlı gelişen koroid neovaskülarizasyonun İVR ile tedavisi anatomik ve fonksiyonel açıdan başarılı sonuçlar sağlamaktadır.

🔖

Cite This Article

ŞENGÜL, E. A., ARTUNAY, Ö., YÜZBAŞIOĞLU, Ö., RASİER, R., ŞENEL, A., BAHÇECİOĞLU, H. (2010). Results of intravitreal ranibizumab treatment for choroidal neovascularization secondary to age-related macular degeneration. Retina-Vitreus, Cilt: 18 - Sayı: 2, 143–148. https://ajindex.com/articles/308141

References (18)

  1. Bressler NM.: Age-related macular degeneration is the leading cause of blindness. JAMA. 2004;291:1900-1901
  2. Friedman DS, O’Colmain BJ, Munoz B, et al.: Prevalence of agerelated macular degeneration in the United States. Arch Ophthalmol. 2004;122:564-572
  3. Jampol LM, Ebroon DA, Goldbaum MH.: Peripheral proliferative retinopathies: An update on angiogenesis, etiologies and management. Surv Ophthalmol. 1994;38:519-540
  4. Distler O, Neidhart M, Gay RE, et al.: The molecular of angiogenesis. Intern Rev Immunol. 2002;21:33-49
  5. Kağnıcı KB, Özdek Ş.: Yaş tip senil makula dejeneresansında yeni medikal tedavi yöntemleri. Ret-Vit. 2005;13:327-331
  6. Aiello LP, Avery RL, Arrigg PG, et al.: Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med. 1994;331:1480-1487
  7. Oester A, Baffi J, Ambati BK.: Pharmacotherapy targeting ocular neovascularization. Focal Points. 2008;XXVI:1-10
  8. Yalçınbayır Ö, Firozvi A, Akduman L.: Makula dejeneransı tedavisinde yeni bir dönem başlıyor. Ret-Vit. 2005:13:1-7
  9. Adamis AP, Shima DT, Tolentino MJ, et al.: Inhibition of vascular endothelial growth factor prevents retinal ischemia associated iris neovascularization in a nonhuman primate. Arch Ophthalmol. 1996;114:66-71
  10. Gragoudas ES, Adamis AP, Cunningham ET Jr, et al.: Pegaptanib for neovascular age-related macular degeneration. New Engl J Med. 2004;351:2805-2816
  11. Ferrara N.: Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev. 2004;25:58-611
  12. Mulcahy MF, Benson AB.: III. Bevacizumab in the treatment of colorectal cancer. Expert Opin Biol Ther. 2005;5:997-1005
  13. Blick SK, Keating GM, Wagstaff AJ.: Ranibizumab. Drugs. 2007;67:1199-1206
  14. Kenneth TE, Kertes PJ.: Ranibizumab in neovascular age-related macular degeneration.Clin Interv Aging. 2006;1:451-466
  15. Brown DM, Kaiser PK, Michels M, et al.: Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1432-1444
  16. Rosenfeld PJ, Brown DM, Heier JS, et al.: Ranibizumab for neovascular age-related macular degeneration. N Engl J Med. 2006;355:1419-1431
  17. Regillo CD, Brown DM, Abraham P, et al.: Randomized, doub-le-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1. Am J Ophthalmol. 2008;145:239-248
  18. Lalwani GA, Rosenfeld PJ, Fung AE, et al.: A variable-dosing regimen with intravitreal